SELECTBIO Conferences Immuno-Oncology Europe 2019
Immuno-Oncology Europe 2019
Date: October 28 - 29, 2019
Venue: Rotterdam Marriott, Rotterdam, The Netherlands

Keynote Speakers

Stephen Beers

Stephen Beers
Professor of Immunology and Immunotherapy, University of Southampton

Sara Colombetti

Sara Colombetti
Global Head Oncology Discovery Pharmacology, pharma Research and Early Development (pRED), Roche Innovation Center Zurich

Graham Pockley

Graham Pockley
Director and Professor, John van Geest Cancer Research Centre, Nottingham Trent University, CEO, multimmune GmbH

Elena Menietti

Elena Menietti
Scientist, Oncology Discovery Pharmacology, pharma Research and Early Development (pRED), Roche Innovation Center Zurich

Ed Schuuring

Ed Schuuring
Professor in Molecular Oncological Pathology, University Medical Center Groningen

Overview

Immuno-Oncology represents a portfolio of approaches aimed at deploying the immune system against tumor targets in vivo.  There is a growing body of scientific and clinical evidence that these approaches are yielding clinically-actionable strategies for cancer treatment.

The SelectBIO Immuno-Oncology Europe 2019 Conference brings together the key opinion leaders in the immunotherapy and tumor immunology fields to address the most up-to-date strategies for immune therapy and means by which immunotherapies may be rationally-combined with more traditional anti-cancer therapeutics.  This field is converging with biofluid biopsies/liquid biopsies and therefore this conference brings together these two disciplines as they are co-evolving.

This conference also addresses biomarkers and companion diagnostics (CDx) which can be utilized to "target patient populations" suitable for immunotherapies.

Presentations from researchers and clinician-scientists at this conference discuss the most recent themes and clinical data.

Call for Posters

You can also present your research on a poster while attending the meeting. Submit an abstract for consideration now!

Poster Submission Deadline: 21 October 2019

Agenda Topics

  • Biomarkers & Companion Diagnostics for Immunotherapy
  • Checkpoint and Non-Checkpoint Immunotherapies
  • Chimeric Antigen Receptor (CAR) T-Cells in Cancer Immunotherapy
  • Combination Cancer Immunotherapy
  • Costimulatory Molecules for Immunological Activation & Therapeutic Intervention
  • Immunomodulatory Antibodies
  • Preclinical Animal Models for Immuno-Oncology
  • Small Molecules in Cancer Immune Therapy
  • Targeting Signaling Pathways in Cancer as Therapeutic Intervention
  • Targeting the Tumor Microenvironment

Sponsorship and Exhibition Opportunities

For more details, please contact us.

Confirmed Speakers to date

Philip Arlen, President and CEO, Precision Biologics, Inc
Johan Baeck, VP, Clinical Development & Medical Affairs, Jounce Therapeutics
CJ Barnum, Director of Neuroscience, INmune Bio, Inc.
Mark Cragg, Professor and Chair in Experimental Cancer Biology, Centre for Cancer Immunology, University of Southampton, Southampton General Hospital
Saviz Ehyai, Product Specialist, CELLINK
Walter Ferlin, CSO, Light Chain Bioscience
David Giljohann, CEO, Exicure
Radhakrishnan Iyer, Co-Founder & Chief Scientific Officer, Spring Bank Pharmaceuticals, Inc.
James Legg, Senior Vice President of Research, Crescendo Biologics
Lorena Lerner, Vice President, Molecular Biology & Virology, Oncorus
Jeanette H W Leusen, Associate Professor & Head of Immunotherapy Group, University Medical Center Utrecht
Miles Rackliff, Senior Sales Manager - Northern Europe, IsoPlexis
Anish Suri, Senior vice President and Chief Scientific Officer, Cue Biopharma, Inc.
RJ Tesi, CEO/CMO, Inmune Bio Inc
Nathaniel Wang, Head of R&D, Synthetic Genomics


Corporate Sponsors Media Sponsors Official Journal Partner Networking
Drug Discovery WoMetaTagsrld U-Networks
Choose your language
Japanese
Traditional Chinese
Simplified Chinese
Korean


Update History
2019/09/18
Agenda,Speaker updated
2019/08/16
Agenda,Speaker,Sponsor updated
2019/07/11
Agenda,Speaker updated